213 completed, 80 terminated, 51 active not recruiting, 43 recruiting. 429 Phase 2, 94 Phase 1, 13 Phase 3.
Follow Rituxan: new trials by email Literature Review of Rituxan trials Research Report on Rituxan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Recruiting | University of Utah | 23 | 2026-11-05 | 2026-11-09 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 43 | 2026-07-27 | 2026-08-28 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma CD19 t-haNK- IV Administration, N-803, rituximab - Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2026-04-01 | 2026-03-17 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL Capivasertib, Venetoclax, Rituximab - Leukemia, Lymphoma | Phase 1 / Phase 2 | Recruiting | University of Chicago | 104 | 2026-03-17 | 2026-03-04 |
| SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas SB-4826, Rituximab - Non Hodgkin Lymphoma, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of California, San Diego | 48 | 2026-02-18 | 2026-03-05 |
| Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Venetoclax, Rituximab - Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | 33 | 2026-02-11 | 2026-03-13 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) Loncastuximab Tesirine, Rituximab - Relapsed or Refractory Large B-cell Lymphoma | Phase 2 | Recruiting | University of Utah | 29 | 2025-08-25 | 2026-10-16 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-10-30 |
Showing 20 of 429. Sign in to see all of them.
Lymphoma (92) · Leukemia, Lymphocytic, Chronic, B-Cell (87) · Lymphoma, Mantle-Cell (86) · Lymphoma, Large B-Cell, Diffuse (84) · Lymphoma, Non-Hodgkin (77) · Lymphoma, Follicular (68) · Burkitt Lymphoma (48) · Lymphoma, B-Cell, Marginal Zone (48) · Waldenstrom Macroglobulinemia (42) · Leukemia (41) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (39) · Hodgkin Disease (30) · Lymphoma, B-Cell (29) · Lymphoma, Large-Cell, Immunoblastic (20) · Recurrence (14)
M.D. Anderson Cancer Center (99) · National Cancer Institute (NCI) (42) · University of Washington (13) · City of Hope Medical Center (11) · Northwestern University (11) · Dana-Farber Cancer Institute (10) · Fred Hutchinson Cancer Center (10) · Mayo Clinic (8) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · Weill Medical College of Cornell University (7) · University of Miami (6) · University of Nebraska (6) · Massachusetts General Hospital (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Eastern Cooperative Oncology Group (4)
United States (396) · Canada (15) · Italy (11) · United Kingdom (11) · France (9) · Australia (8) · Spain (8) · Czechia (7) · Germany (7) · Poland (7) · Belgium (6) · China (4) · Hungary (4) · Israel (4) · Sweden (4)
Elias Jabbour (7) · Ajay Gopal (4) · Daniel O. Persky, MD (4) · Izidore S. Lossos, MD (4) · Richard Burt, MD (4) · Alessandra Ferrajoli, MD (3) · Andrew M. Evens, DO, MS (3) · Elias Jabbour, MD (3) · Felipe Samaniego, MD (3) · Issa F. Khouri, MD (3) · Julie M Vose, MD (3) · Nathan Fowler, MD (3) · Paul Szabolcs, MD (3)
PMID 39319495, PMID 41671463, PMID 23834234, PMID 24224624, PMID 30125215, PMID 33735476, PMID 34515338, PMID 34797699, PMID 35952327, PMID 40550489, PMID 12011123, PMID 12353309, PMID 12907446, PMID 15389904, PMID 18713945, PMID 19118065, PMID 20023215, PMID 20038221, PMID 20039397, PMID 20039413, PMID 20058208, PMID 20142586, PMID 20223728, PMID 20647199, PMID 20956803, PMID 21073974, PMID 21098574, PMID 21239695, PMID 21325353, PMID 21360491, PMID 21440503, PMID 21478218, PMID 21508413, PMID 21756035, PMID 21821712, PMID 22269862, PMID 22282683, PMID 22357140, PMID 22371887, PMID 22563089, PMID 22586182, PMID 22677155, PMID 22734071, PMID 22835045, PMID 22975753, PMID 23124321, PMID 23124935, PMID 23279219, PMID 23426943, PMID 23514433
P30CA015704 (10), P30CA033572 (9), P30CA016672 (8), P30CA006973 (5), P30CA015083 (5), U10CA021115 (5), U10CA180821 (5), P30CA036727 (4), U10CA031946 (4), U10CA032102 (4), P30CA023074 (3), P30CA060553 (3), P50CA096888 (3), U10CA025224 (3), U10CA180820 (3)